PLRX - Pliant Therapeutics Inc
IEX Last Trade
13.27
0.100 0.754%
Share volume: 254,751
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$13.17
0.10
0.76%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-08 | 2022-11-08 | 2023-03-09 | 2023-05-09 | 2023-08-09 | 2023-11-09 | 2024-02-27 | 2024-05-06 | |
| Assets | |||||||||
| Total Assets | 184.619 M | 377.181 M | 350.613 M | 597.881 M | 574.891 M | 540.464 M | 512.154 M | 521.605 M | |
| Current Assets | 173.526 M | 365.965 M | 340.311 M | 588.227 M | 565.701 M | 534.335 M | 505.502 M | 489.898 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 4.857 M | 4.159 M | 7.058 M | 7.533 M | 8.885 M | 10.640 M | 11.257 M | 7.509 M | |
| Short Term Investments | 4.857 M | 4.159 M | 7.058 M | 7.533 M | 8.885 M | 10.640 M | 11.257 M | 7.509 M | |
| Total Receivables | 5.072 M | 1.565 M | 2.066 M | 3.380 M | 1.657 M | 83.000 K | 0.000 | 0.000 | |
| Current Cash | 163.597 M | 360.241 M | 331.187 M | 577.314 M | 555.159 M | 523.612 M | 494.245 M | 482.389 M | |
| Total Non-current Assets | 11.093 M | 11.216 M | 10.302 M | 9.654 M | 9.190 M | 6.129 M | 6.652 M | 31.707 M | |
| Property Plant Equipment | 4.534 M | 4.799 M | 4.486 M | 4.197 M | 4.332 M | 3.969 M | 3.567 M | 5.605 M | |
| Other Assets | 6.559 M | 6.417 M | 5.816 M | 5.457 M | 4.858 M | 2.160 M | 1.603 M | 24.620 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 184.619 M | 377.181 M | 350.613 M | 597.881 M | 574.891 M | 540.464 M | 512.154 M | 521.605 M | |
| Total liabilities | 36.831 M | 40.187 M | 37.271 M | 35.961 M | 41.826 M | 37.416 M | 38.578 M | 84.273 M | |
| Total current liabilities | 22.553 M | 26.161 M | 23.913 M | 23.153 M | 29.520 M | 27.395 M | 28.524 M | 30.391 M | |
| Accounts Payable | 3.116 M | 3.206 M | 1.580 M | 1.419 M | 2.310 M | 3.360 M | 4.531 M | 7.327 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 2.042 M | 2.649 M | 2.457 M | 2.380 M | 2.232 M | 2.061 M | 1.318 M | 773.000 K | |
| Long term debt | 14.278 M | 14.026 M | 13.358 M | 12.808 M | 12.306 M | 10.021 M | 10.054 M | 53.882 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 147.788 M | 336.994 M | 313.342 M | 561.920 M | 533.065 M | 503.048 M | 473.576 M | 437.332 M | |
| Common stock | 36.173 M | 46.799 M | 48.975 M | 56.058 M | 59.173 M | 59.688 M | 59.957 M | 60.181 M | |
| Retained earnings | -272.737 M | -303.352 M | -338.412 M | -375.960 M | -417.152 M | -458.639 M | -499.748 M | -546.703 M |